Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04948645 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT04948645 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 31 participants.
The verdict
NCT04948645, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
Fosigotifator is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study. Part 1 will be a 4-week, randomized, double-blind, placebo-controlled study; Part 2 will be up to a 152-week active treatment extension (ATE) during which all subjects will receive Fosigotifator.
Interventions
- DRUG Placebo
- DRUG Fosigotifator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-09-22 |
| Est. Completion | 2025-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04948645
The ClinicalTrials.gov registry entry for NCT04948645 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04948645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04948645 about?
NCT04948645 is a clinical study titled "A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis". Fosigotifator is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study. Part 1 will be a 4-week, randomized, double-blind, placebo-controlled study; Part 2 will be up to a 152-week active treatment extension (ATE) during ...
What is the current status of trial NCT04948645?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2021-09-22. Estimated completion is 2025-07-15.
What interventions are being tested in trial NCT04948645?
The interventions under investigation include: Placebo (DRUG), Fosigotifator (DRUG).
Who is sponsoring clinical trial NCT04948645?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.